FDA, EMA team on QbD-based joint reviews

The U.S and the EU are giving joint drug assessments a try. At the core of the three-year pilot: Quality by Design.

The FDA/EMA program will allow parallel evaluation of QbD components in select applications submitted to both agencies at the same time. The pilot, covering only chemical entities, will begin April 1.

The program will cover chemistry, manufacturing and control meeting requests as well as new drug applications and supplemental NDAs. Manufacturer participation is voluntary and the regulators ask for three months' notice before filing.

"Taking into account the global perspective of pharmaceutical manufacturing, and to facilitate the harmonized implementation of the International Conference on Harmonization concepts, the EMA and FDA agreed that experts from both agencies should exchange their views using real applications," the regulators say in a statement.

Pharma QbD uses a science-based approach to drug manufacturing and development as a means of ensuring product quality.

- here's the FDA announcement


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.